Bristol-Myers Squibb And Dana-Farber Cancer Institute Enter Into A Collaboration Agreement As Part Of U.S. Immuno-Oncology Rare Population Malignancy Research Program

NEW YORK & BOSTON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Dana-Farber Cancer Institute today announced that they have entered into a research collaboration agreement as part of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. Dana-Farber Cancer Institute is the latest leading, academic-based cancer center to join the I-O RPM program, which is a multi-institutional initiative focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.

Back to news